Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline characteristics of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Successful enrollment of a diverse clinical trial cohort at risk for cognitive decline.
Whitmer RA, Baker LD, Carrillo MC, Snyder HM, Cleveland ML, Gitelman DR, Kivipelto M, Leng XI, Lovato L, Papp KV, Pavlik VN, Salloway SP, Tangney CC, Farias ST, Williamson JD, Wilmoth S, Woolard N, Yu M, Espeland MA; U.S. POINTER Study Group. Whitmer RA, et al. Among authors: gitelman dr. Alzheimers Dement. 2025 Jun;21(6):e70351. doi: 10.1002/alz.70351. Alzheimers Dement. 2025. PMID: 40556311 Free PMC article. Clinical Trial.
Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).
Baker LD, Snyder HM, Espeland MA, Whitmer RA, Kivipelto M, Woolard N, Katula J, Papp KV, Ventrelle J, Graef S, Hill MA, Rushing S, Spell J, Lovato L, Felton D, Williams BJ, Ghadimi Nouran M, Raman R, Ngandu T, Solomon A, Wilmoth S, Cleveland ML, Williamson JD, Lambert KL, Tomaszewski Farias S, Day CE, Tangney CC, Gitelman DR, Matongo O, Reynolds T, Pavlik VN, Yu MM, Alexander AS, Elbein R, McDonald AM, Salloway S, Wing RR, Antkowiak S, Morris MC, Carrillo MC; U.S. POINTER Study Group. Baker LD, et al. Among authors: gitelman dr. Alzheimers Dement. 2024 Feb;20(2):769-782. doi: 10.1002/alz.13365. Epub 2023 Sep 30. Alzheimers Dement. 2024. PMID: 37776210 Free PMC article. Clinical Trial.
Optimizing quantification of MK6240 tau PET in unimpaired older adults.
Harrison TM, Ward TJ, Murphy A, Baker SL, Dominguez PA, Koeppe R, Vemuri P, Lockhart SN, Jung Y, Harvey DJ, Lovato L, Toga AW, Masdeu J, Oh H, Gitelman DR, Aggarwal N, Snyder HM, Baker LD, DeCarli C, Jagust WJ, Landau SM; U.S. POINTER Study Group. Harrison TM, et al. Among authors: gitelman dr. Neuroimage. 2023 Jan;265:119761. doi: 10.1016/j.neuroimage.2022.119761. Epub 2022 Nov 28. Neuroimage. 2023. PMID: 36455762 Free PMC article. Clinical Trial.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Clinical Manifestations.
Tariot PN, Petersen M, Gitelman DR, Govia I. Tariot PN, et al. Among authors: gitelman dr. Alzheimers Dement. 2025 Dec;21 Suppl 3(Suppl 3):e103023. doi: 10.1002/alz70857_103023. Alzheimers Dement. 2025. PMID: 41447477 Free PMC article.
Public Health.
Espeland MA, Snyder HM, Baker LD, Whitmer RA, Kivipelto M, Alexander A, Antkowiak S, Cleveland M, Day CE, Elbein R, Farias ST, Felton DM, Gitelman DR, Howard M, Lambert K, Lovato L, Leng XI, Matongo O, McDonald AM, Papp KV, Pavlik V, Raman R, Salloway S, Tangney CC, Williams BJ, Wing RR, Rissman RA, Wilmoth S, Woolard N, Yu M, Carrillo MC; U.S. POINTER Study Group. Espeland MA, et al. Among authors: gitelman dr. Alzheimers Dement. 2025 Dec;21 Suppl 6(Suppl 6):e096524. doi: 10.1002/alz70860_096524. Alzheimers Dement. 2025. PMID: 41433857 Free PMC article. Clinical Trial.
Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial.
Baker LD, Espeland MA, Whitmer RA, Snyder HM, Leng X, Lovato L, Papp KV, Yu M, Kivipelto M, Alexander AS, Antkowiak S, Cleveland M, Day C, Elbein R, Tomaszewski Farias S, Felton D, Garcia KR, Gitelman DR, Graef S, Howard M, Katula J, Lambert K, Matongo O, McDonald AM, Pavlik V, Raman R, Salloway S, Tangney C, Ventrelle J, Wilmoth S, Willliams BJ, Wing R, Woolard N, Carrillo MC. Baker LD, et al. Among authors: gitelman dr. JAMA. 2025 Aug 26;334(8):681-691. doi: 10.1001/jama.2025.12923. JAMA. 2025. PMID: 40720610 Clinical Trial.
Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.
Monane M, Maraganore DM, Carlile RM, Johnson KG, Merrill DA, Gitelman DR, Sharlin KS, VandeVrede LA, George KK, Wang J, West T, Jacobs L, Verghese PB, Braunstein JB. Monane M, et al. Among authors: gitelman dr. Diagnostics (Basel). 2025 Jan 13;15(2):167. doi: 10.3390/diagnostics15020167. Diagnostics (Basel). 2025. PMID: 39857051 Free PMC article.
99 results